Cytomegalovirus (CMV) vaccine

A very harmful infection for mother and child - Cytomegalovirus

Cytomegalovirus infection is common, with a prevalence in the adult population. Although initial (primary) CMV infections in children and adults are rarely symptomatic, transmitted in utero (in the mother's uterus) CMV infection can result in severe disability for life.

Most at risk are infants born to mothers who acquire CMV infection during pregnancy, which occurs in about 1/3 of these newborns. A congenital CMV infection can occur at any time during pregnancy.

Overall, 10-15% of infants born to women with CMV infection during pregnancy are symptomatic at birth, and among these symptomatic infants, 4-12% die in their first year of life and 70% 80% survive to suffer from permanent disabilities.

We are conducting a clinical study to assess the efficacy, safety and immunogenicity of an investigational vaccine against (CMV) in healthy women aged 18 to 40 years.

To participate, you must:

• Be between 18 and 40 years old
• Be in contact with children aged 5 and under for 8 hours per week

You will be reimbursed for expenses related to the study during your participation and you will be monitored by a medical team throughout the process.